The flow-metabolic phenotype of primary colorectal cancer: Assessment by integrated 18F-FDG PET/perfusion CT with histopathologic correlation

Journal of Nuclear Medicine

Volumn 53, Issue 5, 2012, Pages 687-692

  Goh, Vicky ^a   Engledow, Alec ^b   Rodriguez Justo, Manuel ^c   Shastry, Manu ^d   Peck, Jacquie ^b   Blackman, Glen ^b   Endozo, Raymondo ^b   Taylor, Stuart ^b   Halligan, Steve ^b   Ell, Peter ^d   Groves, Ashley M ^d  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

18F FDG; Colorectal cancer; Computed tomography; Helical; Perfusion CT; Positron emission tomography

Indexed keywords

ENDOGLIN; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1; IOHEXOL; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CORRELATION ANALYSIS; FEMALE; GLUCOSE METABOLISM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOXIA; IN VIVO STUDY; MALE; METABOLISM; MICROVASCULATURE; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; TUMOR BLOOD FLOW; TUMOR METABOLISM;

AGED; AGED, 80 AND OVER; CELL HYPOXIA; COLORECTAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PERFUSION IMAGING; PHENOTYPE; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; REGIONAL BLOOD FLOW;

EID: 84860745641     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.098525     Document Type: Article

References (41)

1. Swedish rectal cancer trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997;336:980-987.
2. Peeters KC, Marijnen CA, Nagtegaal ID, et al. The TME trial after a median follow-up of 6 years: Increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg. 2007;246:693-701. (Pubitemid 350035641)
3. van Gijn W, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year followup of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011; 12:575-582.
4. Bosset JF, Calais G, Mineur L, et al. Enhanced tumoricidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: Preliminary results-EORTC 22921. J Clin Oncol. 2005;23:5620-5627.
5. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114-1123. (Pubitemid 44394918)
6. Chau I, Allen M, Cunningham D, et al. Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer. Br J Cancer. 2003;88:1017-1024. (Pubitemid 36560768)
7. Chau I, Brown G, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol. 2006;24:668-674. (Pubitemid 46630432)
8. Chua YJ, Barbachano Y, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: A phase 2 trial. Lancet Oncol. 2010;11:241-248.
9. Fernández-Martos C, Pericay C, Aparicio J, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol. 2010;28:859-865.
10. MERCURY Study Group: Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: Prospective observational study. BMJ. 2006;333:779.
11. Smith NJ, Bees N, Barbachano Y, Norman AR, Swift RI, Brown G. Preoperative computed tomography staging of nonmetastatic colon cancer predicts outcome: Implications for clinical trials. Br J Cancer. 2007;96:1030-1036. (Pubitemid 46608307)
12. NCCN practice guidelines. National Comprehensive Cancer Network Web site. Available at: Http://www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed March 9, 2012.
13. Sargent DJ, Patiyil S, Yothers G, et al. ACCENT Group. End points for colon cancer adjuvant trials: Observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol. 2007;25:4569-4574. (Pubitemid 350035314)
14. Kantorová I, Lipska L, Belohlavek O, et al. Routine 18F-FDG PET preoperative staging of colorectal cancer: Comparison with conventional staging and its impact on treatment decision making. J Nucl Med. 2003;44:1784-1788. (Pubitemid 39663310)
15. Abdel-Nabi H, Doerr RJ, Lamonica DM, et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: Correlation with histopathologic and CT findings. Radiology. 1998;206:755-760. (Pubitemid 28128526)
16. Miles KA, Williams RE. Warburg revisited: Imaging tumour blood flow and metabolism. Cancer Imaging. 2008;8:81-86. (Pubitemid 351517291)
17. Martoni AA, Di Fabio F, Pinto C, et al. Prospective study on the FDG-PET/CT predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer. Ann Oncol. 2011;22:650-656.
18. Padhani AR, Miles KA. Multiparametric imaging of tumor response to therapy. Radiology. 2010;256:348-364.
19. Mankoff DA, Dunnwald LK, Gralow JR, et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med. 2003;44:1806-1814. (Pubitemid 39663314)
20. St Lawrence KS, Lee TY. An adiabatic approximation to the tissue homogeneity model for water exchange in the brain: I. Theoretical derivation. J Cereb Blood Flow Metab. 1998;18:1365-1377. (Pubitemid 28559684)
21. Airley R, Loncaster J, Davidson S, et al. Glucose transporter Glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res. 2001;7:928-934. (Pubitemid 32708731)
22. Simiantonaki N, Taxeidis M, Jayasinghe C, et al. Hypoxia-inducible factor 1 alpha expression increases during colorectal carcinogenesis and tumour progression. BCM Cancer. 2008;8:320.
23. Tateishi U, Nishihara H, Tsukamoto E, Morikawa T, Tamaki N, Miyasaka K. Lung tumors evaluated with FDG-PET and dynamic CT: The relationship between vascular density and glucose metabolism. J Comput Assist Tomogr. 2002;26:185-190. (Pubitemid 34233362)
24. Miles KA, Griffiths MR, Keith CJ. Blood flow-metabolic relationships are dependent on tumour size in non-small cell lung cancer: A study using quantitative contrast-enhanced computer tomography and positron emission tomography. Eur J Nucl Med Mol Imaging. 2006;33:22-28. (Pubitemid 41785305)
25. Hirasawa S, Tsushima Y, Takei H, et al. Inverse correlation between tumor perfusion and glucose uptake in human head and neck tumors. Acad Radiol. 2007;14:312-318. (Pubitemid 46329457)
26. Bisdas S, Spicer K, Rumboldt Z. Whole-tumor perfusion CT parameters and glucose metabolism measurements in head and neck squamous cell carcinomas: A pilot study using combined positron-emission tomography/CT imaging. AJNR. 2008;29:1376-1381.
27. Groves AM, Wishart GC, Shastry M, et al. Metabolic-flow relationships in primary breast cancer: Feasibility of combined PET/dynamic contrast-enhanced CT. Eur J Nucl Med Mol Imaging. 2009;36:416-421.
28. Veit-Haibach P, Treyer V, Strobel K, et al. Feasibility of integrated CT-liver perfusion in routine FDG-PET/CT. Abdom Imaging. 2010;35:528-536.
29. Dunnwald LK, Gralow JR, Ellis GK, et al. Tumor metabolism and blood flow changes by positron emission tomography: Relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol. 2008;26:4449-4457.
30. Specht JM, Kurland BF, Montgomery SK, et al. Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer. Clin Cancer Res. 2010;16:2803-2810.
31. Tseng J, Dunnwald LK, Schubert EK, et al. 18F-FDG kinetics in locally advanced breast cancer: Correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy. J Nucl Med. 2004;45:1829-1837. (Pubitemid 47618439)
32. Komar G, Kauhanen S, Liukko K, et al. Decreased blood flow with increased metabolic activity: A novel sign of pancreatic tumor aggressiveness. Clin Cancer Res. 2009;15:5511-5517.
33. Hawkes EA, Cunningham D, Tait D, Brown G, Chau I. Neoadjuvant chemotherapy alone for early-stage rectal cancer: An evolving paradigm? Semin Radiat Oncol. 2011;21:196-202.
34. Van Cutsem E, Dicato M, Haustermans K, et al. The diagnosis and management of rectal cancer: Expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. Ann Oncol. 2008;19(suppl 6):vi1-vi8.
35. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer Verlag; 2009.
36. Figueredo A, Coombes ME, Mukherjee S. Cochrane Database Syst Rev. 2008;3: CD005390.
37. Desolneux G, Burtin P, Lermite E, Bergamaschi R, Hamy A, Arnaud JP. Prognostic factors in node-negative colorectal cancer: A retrospective study from a prospective database. Int J Colorectal Dis. 2010;25:829-834.
38. Ng CS, Kodama Y, Mullani NA, et al. Tumor blood flow measured by perfusion computed tomography and 15O-labeled water positron emission tomography: A comparison study. J Comput Assist Tomogr. 2009;33:460-465.
39. Liévre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992-3995.
40. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-1634.
41. Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatinbased first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial. Lancet. 2011; 377:2103-2114.